Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy

C. N. Sternberg, A. Molina, S. North, P. Mainwaring, K. Fizazi, Y. Hao, M. Rothman, D. D. Gagnon, T. Kheoh, C. M. Haqq, C. Cleeland, J. S. de Bono, H. I. Scher

    Research output: Contribution to journalArticlepeer-review

    80 Citations (Scopus)

    Abstract

    Background: Fatigue is a common, debilitating side-effect of prostate cancer and its treatment. Patient-reported fatigue was evaluated as part of COU-AA-301, a randomized, placebo-controlled, phase III trial of abiraterone acetate and prednisone versus placebo and prednisone in metastatic castration-resistant prostate cancer (mCRPC) patients after docetaxel chemotherapy. This is the first phase III study in advanced prostate cancer to evaluate fatigue outcomes using a validated fatigue-specific instrument. Patients and methods: The Brief Fatigue Inventory (BFI) questionnaire was used to measure patient-reported fatigue intensity and fatigue interference with activities of daily life. All analyses were conducted using prespecified responder definitions of clinically meaningful changes. Results: A total of 797 patients were randomized to abiraterone acetate and prednisone, and 398 were randomized to placebo and prednisone. Compared with prednisone alone, in patients with clinically significant fatigue at baseline, abiraterone acetate and prednisone significantly increased the proportion of patients reporting improvement in fatigue intensity (58.1% versus 40.3%, P = 0.0001), improved fatigue interference (55.0% versus 38.0%, P = 0.0075), and accelerated improvement in fatigue intensity (median 59 days versus 194 days, P = 0.0155). Conclusions: In patients with mCRPC progressing after docetaxel chemotherapy, abiraterone acetate and prednisone yielded clinically meaningful improvements in patient-reported fatigue compared with prednisone alone.

    Original languageEnglish
    Pages (from-to)1017-1025
    Number of pages9
    JournalAnnals of Oncology
    Volume24
    Issue number4
    DOIs
    Publication statusPublished - 1 Jan 2013

    Keywords

    • Advanced prostate cancer
    • Palliation
    • Patient-reported outcome

    Cite this